These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25697114)

  • 1. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
    Takeuchi M; Sakasai-Sakai A; Takata T; Ueda T; Takino J; Tsutsumi M; Hyogo H; Yamagishi S
    Med Hypotheses; 2015 May; 84(5):490-3. PubMed ID: 25697114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.
    Takeuchi M; Takino J; Sakasai-Sakai A; Takata T; Ueda T; Tsutsumi M; Hyogo H; Yamagishi S
    World J Hepatol; 2014 Dec; 6(12):880-93. PubMed ID: 25544875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relevance of Toxic AGEs (TAGE) Cytotoxicity to NASH Pathogenesis: A Mini-Review.
    Sakasai-Sakai A; Takata T; Takino JI; Takeuchi M
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30813302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Takino J; Nagamine K; Hori T; Sakasai-Sakai A; Takeuchi M
    World J Hepatol; 2015 Oct; 7(23):2459-69. PubMed ID: 26483867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
    Takeuchi M; Takino J; Yamagishi S
    Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis.
    Hyogo H; Yamagishi S; Iwamoto K; Arihiro K; Takeuchi M; Sato T; Ochi H; Nonaka M; Nabeshima Y; Inoue M; Ishitobi T; Chayama K; Tazuma S
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1112-9. PubMed ID: 17559366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
    Takeuchi M; Yamagishi S
    J Alzheimers Dis; 2009; 16(4):845-58. PubMed ID: 19387117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Intracellular TAGE and the TAGE-RAGE-ROS Axis in the Onset and Progression of NAFLD/NASH.
    Sakasai-Sakai A; Takeda K; Takeuchi M
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells.
    Sakasai-Sakai A; Takata T; Takeuchi M
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
    Kimura Y; Hyogo H; Yamagishi S; Takeuchi M; Ishitobi T; Nabeshima Y; Arihiro K; Chayama K
    J Gastroenterol; 2010 Jul; 45(7):750-7. PubMed ID: 20112031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases.
    Takeuchi M
    Diagnostics (Basel); 2016 Jun; 6(2):. PubMed ID: 27338481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.
    Takeuchi M; Takino J; Yamagishi S
    J Ophthalmol; 2010; 2010():170393. PubMed ID: 20652047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
    Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
    APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
    Shimomura Y; Takaki A; Wada N; Yasunaka T; Ikeda F; Maruyama T; Tamaki N; Uchida D; Onishi H; Kuwaki K; Nakamura S; Nouso K; Miyake Y; Koike K; Tomofuji T; Morita M; Yamamoto K; Okada H
    Intern Med; 2017; 56(3):243-251. PubMed ID: 28154266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary glycotoxins exacerbate progression of experimental fatty liver disease.
    Leung C; Herath CB; Jia Z; Goodwin M; Mak KY; Watt MJ; Forbes JM; Angus PW
    J Hepatol; 2014 Apr; 60(4):832-8. PubMed ID: 24316518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular Toxic AGEs (TAGE) Triggers Numerous Types of Cell Damage.
    Takeuchi M; Sakasai-Sakai A; Takata T; Takino JI; Koriyama Y; Kikuchi C; Furukawa A; Nagamine K; Hori T; Matsunaga T
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33808036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.